Wydanie 3/2016
str. 65 - 69

Program lekowy „Leczenie neowaskularnej (wysiękowej) postaci zwyrodnienia plamki związanego z wiekiem” w Polsce – od kwalifikacji do leczenia

Małgorzata Figurska, Marek Rękas

Klinika Okulistyki CSK MON
Wojskowy Instytut Medyczny w Warszawie
Kierownik: płk, prof. dr hab. n. med. Marek Rękas

Summary: Treatment Program "Treatment of exudative (wet) form of age-related macular degeneration has been established in Poland since October 2015. It is the first ophthalmological program out of 40 non-oncological treatment programs in our country. The program is executed in 134 centers, contracted with National Health Fund. 11 thousand people with exudative form of age-related macular degeneration have already been enrolled to the program and the number of qualified patients is increasing. Since the beginning of the program most patients were treated in following regions: Silesia, Lower Silesia, Mazovia, Malopolska, Kujawsko-Pomorskie, Lodz. Patients are qualified by Coordinating Team under the leadership of the Chairman, appointed by the President of the National Health Fund. The aim of tthis article is to present the rules of treatment patients in the program. The program enables treatment with either the fusion protein aflibercept or the monoclonal antibody ranibizumab. The article discusses the principles of patients enrolment through electronic Central System, current eligibility criteria for qualification to the Treatment Program, exclusion from the treatment, suspension of treatment, changes in medication type or dosage. Examination data vital for qualification is presented. Monitoring of the patient is discussed. In conclusion, attention was paid to measures of speeding up the process of electronic application in order to provide the fastest qualification of exudative form of age-related macular degeneration patients. Fast treatment implementation after Coordinating Team approval was emphasized.

Słowa kluczowe: wysiękowe zwyrodnienie plamki związane z wiekiem, program lekowy, aflibercept, ranibizumab, kwalifikacja do programu, dawkowanie leków, wizyty monitorujące.

Keywords: exudative age-related macular degeneration, treatment program, aflibercept, ranibizumab, program qualification, medication dosage, control visits.